H-Index
10
Scimago Lab
powered by Scopus
eISSN: 2325-4416
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST

Logo

MSMbanner
AmJCaseRep

Annals
ISI-Home

Effect of Sugammadex on Postoperative Bleeding and Coagulation Parameters After Septoplasty: A Randomized Prospective Study

Nilay Taş, Hakan Korkmaz, Özgür Yağan, Mukadder Korkmaz

Department of Anesthesiology, School of Medicine, Ordu University, Ordu, Turkey

Med Sci Monit 2015; 21:2382-2386

DOI: 10.12659/MSM.894971

Available online:

Published: 2015-08-14


BACKGROUND: Sugammadex is a reversal agent with well known advantages but it’s effects on haemostasis and bleeding have been a topic of interest. Septoplasty is a common surgical procedure with postoperative respiratory complications and bleeding. The aim of this study is to investigate the effects of sugammadex on postoperative coagulation parameters and bleeding after septoplasty procedure.
MATERIAL AND METHODS: In this randomized controlled study, fifty patients were grouped into two groups; neostigmine (Group N) vs. sugammadex (Group S). For the evaluation of PT, aPTT and INR, blood samples were taken for at the postoperative 120th minutes and alteration of these values with respect to preoperative values were documented. Postoperative bleeding was measured by evaluating the amount of blood absorbed on the nasal tip dressing during 3 hours postoperatively.
RESULTS: Postoperative bleeding amount was significantly higher in the Group S compared to Group N (p=0.013). No significant difference was observed between two groups according to coagulation parameters (PT; p=0.953, aPTT; p=0.734, INR; p=0.612).
CONCLUSIONS: Sugammadex was associated with higher amount of postoperative bleeding than neostigmine in septoplasty patients. In surgical procedures having high risk of bleeding the safety of sugammadex need to be verified.

Keywords: Blood Loss, Surgical - prevention & control, Blood Coagulation - drug effects, Adult, Postoperative Complications - prevention & control, Prospective Studies, young adult, gamma-Cyclodextrins - therapeutic use



Back